A fatal case involving a clonazepam prodrug shows why a negative parent-drug blood result does not necessarily exclude exposure.
The report concerned a 20-year-old man with clonazafone, fluoro-etonitazene, and amphetamine exposure. Clonazafone was detected in urine, muscle, and stomach contents but not in peripheral blood, heart blood, or vitreous humor at the reported analytical limit.
Blood contained clonazepam at 1.5 ng/mL and 7-amino-clonazepam at 140 ng/mL, alongside amphetamine and fluoro-etonitazene. High-resolution screening identified desglycylclonazafone in urine and stomach contents, as well as additional metabolites.
Clonazafone is a prodrug that can lead to clonazepam through an intermediate. The combined specimen and metabolite pattern was therefore more informative than the blood test for clonazafone alone. Some reported quantities were semiquantitative, which should remain explicit when comparing matrices.
The authors considered the death a mixed-drug intoxication. A single case cannot isolate the contribution of each substance or establish a fatal concentration for clonazafone. For forensic interpretation, keep matrix, analytical scope, detection limits, metabolism, and co-exposures together. Neither a negative parent result nor a low concentration of one detected drug resolves the entire toxicological history.
Original analysis of the supplied journal article, identified as PMC12956958.